Zenas BioPharma Balance Sheet Health
Financial Health criteria checks 6/6
Zenas BioPharma has a total shareholder equity of $160.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $200.0M and $39.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$183.93m |
| Equity | US$160.83m |
| Total liabilities | US$39.12m |
| Total assets | US$199.95m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ZBIO's short term assets ($188.6M) exceed its short term liabilities ($39.1M).
Long Term Liabilities: ZBIO's short term assets ($188.6M) exceed its long term liabilities ($14.0K).
Debt to Equity History and Analysis
Debt Level: ZBIO is debt free.
Reducing Debt: ZBIO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZBIO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ZBIO has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 69% each year.